- Home
- TLPH vs ABP Comparison
TLPH vs ABP Comparison
Compare TLPH & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- ABP
- Stock Information
- Founded
- TLPH 2005
- ABP 2004
- Country
- TLPH United States
- ABP United States
- Employees
- TLPH N/A
- ABP N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- TLPH Health Care
- ABP Health Care
- Exchange
- TLPH Nasdaq
- ABP Nasdaq
- Market Cap
- TLPH 10.6M
- ABP 12.3M
- IPO Year
- TLPH 2011
- ABP N/A
- Fundamental
- Price
- TLPH $0.54
- ABP $0.25
- Analyst Decision
- TLPH Strong Buy
- ABP Strong Buy
- Analyst Count
- TLPH 1
- ABP 1
- Target Price
- TLPH $6.00
- ABP $4.00
- AVG Volume (30 Days)
- TLPH 3.4M
- ABP 6.1M
- Earning Date
- TLPH 08-14-2025
- ABP 08-13-2025
- Dividend Yield
- TLPH N/A
- ABP N/A
- EPS Growth
- TLPH N/A
- ABP N/A
- EPS
- TLPH N/A
- ABP N/A
- Revenue
- TLPH $27,000.00
- ABP $183,000.00
- Revenue This Year
- TLPH N/A
- ABP N/A
- Revenue Next Year
- TLPH $14,533.26
- ABP N/A
- P/E Ratio
- TLPH N/A
- ABP N/A
- Revenue Growth
- TLPH N/A
- ABP 154.17
- 52 Week Low
- TLPH $0.38
- ABP $0.15
- 52 Week High
- TLPH $1.19
- ABP $11.19
- Technical
- Relative Strength Index (RSI)
- TLPH 65.80
- ABP 48.68
- Support Level
- TLPH $0.40
- ABP $0.23
- Resistance Level
- TLPH $0.62
- ABP $0.26
- Average True Range (ATR)
- TLPH 0.06
- ABP 0.02
- MACD
- TLPH 0.01
- ABP -0.00
- Stochastic Oscillator
- TLPH 52.81
- ABP 29.81
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.